Entrar

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol), glyburide (Diabeta), and glimepiride (Amaril), are preferred due to their enhanced potency and shorter duration of action.

The mechanism of sulfonylureas involves binding to ATP-sensitive potassium channels on pancreatic β cells. This interaction triggers cell membrane depolarization, leading to calcium influx and subsequent insulin release, effectively lowering blood glucose levels. Beyond stimulating insulin secretion, sulfonylureas reduce hepatic glucose production and augment peripheral glucose utilization, contributing to improved glycemic control. They are primarily prescribed when diet and exercise alone fail to manage type 2 diabetes and can be used solo or combined with other antidiabetic medications.

Despite their efficacy, sulfonylureas may cause adverse effects such as hypoglycemia, weight gain, and gastrointestinal disturbances. Hypoglycemia is the most common side effect, particularly in elderly patients or those with impaired kidney function. Careful dosage and monitoring are required to mitigate these risks. In conclusion, sulfonylureas are potent oral hypoglycemic agents that stimulate insulin release and improve insulin sensitivity, playing a critical role in managing type 2 diabetes. However, their use requires careful monitoring due to potential adverse effects.

Do Capítulo 25:

article

Now Playing

25.10 : Oral Hypoglycemic Agents: Sulfonylureas

Insulin and Hypoglycemic Drugs

120 Visualizações

article

25.1 : Glucose Homeostasis: Regulation of Blood Glucose

Insulin and Hypoglycemic Drugs

1.1K Visualizações

article

25.2 : Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

Insulin and Hypoglycemic Drugs

942 Visualizações

article

25.3 : Insulin: The Receptor and Signaling Pathways

Insulin and Hypoglycemic Drugs

963 Visualizações

article

25.4 : Pathophysiology of Diabetes

Insulin and Hypoglycemic Drugs

755 Visualizações

article

25.5 : Diabetes: Symptoms, Diagnosis, and Complications

Insulin and Hypoglycemic Drugs

455 Visualizações

article

25.6 : Diabetes: Management and Pharmacotherapy

Insulin and Hypoglycemic Drugs

196 Visualizações

article

25.7 : Insulin: Biosynthesis, Chemistry, and Preparation

Insulin and Hypoglycemic Drugs

261 Visualizações

article

25.8 : Insulin Formulations: Types and Delivery

Insulin and Hypoglycemic Drugs

125 Visualizações

article

25.9 : Insulin: Dosing Regimen and Adverse Effects

Insulin and Hypoglycemic Drugs

104 Visualizações

article

25.11 : Oral Hypoglycemic Agents: Biguanides and Glitazones

Insulin and Hypoglycemic Drugs

122 Visualizações

article

25.12 : Oral Hypoglycemic Agents: Glinides

Insulin and Hypoglycemic Drugs

103 Visualizações

article

25.13 : Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Insulin and Hypoglycemic Drugs

98 Visualizações

article

25.14 : Glucagon-like Receptor Agonists

Insulin and Hypoglycemic Drugs

236 Visualizações

article

25.15 : Dipeptidyl Peptidase 4 Inhibitors

Insulin and Hypoglycemic Drugs

111 Visualizações

See More

JoVE Logo

Privacidade

Termos de uso

Políticas

Pesquisa

Educação

SOBRE A JoVE

Copyright © 2025 MyJoVE Corporation. Todos os direitos reservados